RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Inflammation and cancer cell survival: TRAF2 as a key player.
Inflammation and cancer cell survival: TRAF2 as a key player.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
TNF受体相关因子2(TRAF2)在生理和病理过程中均发挥关键作用。它参与细胞存活与死亡的调控、组织再生、发育、内质网应激反应、自噬、上皮屏障稳态以及适应性免疫和固有免疫的调节。TRAF2最初因其与TNF受体2(TNFR2)的相互作用而被发现,其含有一个TRAF结构域,能够实现同源和异源寡聚化,从而使其能够与多种受体和信号分子相互作用。虽然TRAF2以介导TNFR1和TNFR2信号传导而最为人所知,但它也调节其他受体通路,包括MAPK、NF-κB和Wnt/β-catenin级联反应。通过调节NF-κB诱导激酶(NIK),TRAF2是替代性NF-κB通路的关键激活因子,将其与炎症性疾病、免疫功能障碍和肿瘤发生联系起来。在固有免疫系统中,TRAF2影响巨噬细胞的分化、活化和存活,并刺激NK 细胞的细胞毒性。在适应性免疫系统中,它抑制效应B细胞和T细胞的活性,同时维持调节性T细胞的功能,从而促进免疫抑制。TRAF2活性缺乏精细调控会导致NF-κB过度激活,驱动慢性炎症和自身免疫。尽管TRAF2可作为抑癌因子,但它主要被描述为促癌因子,因为其表达与多种癌症类型中转移潜能增加和预后较差相关。靶向TRAF2或TRAF2依赖性信号通路可能代表一种有前景的抗癌治疗策略。
TNF receptor-associated factor 2 (TRAF2) plays a crucial role in both physiological and pathological processes. It takes part in the regulation of cell survival and death, tissue regeneration, development, endoplasmic reticulum stress response, autophagy, homeostasis of the epithelial barrier and regulation of adaptive and innate immunity. Initially identified for its interaction with TNF receptor 2 (TNFR2), TRAF2 contains a TRAF domain that enables homo- and hetero-oligomerization, allowing it to interact with multiple receptors and signaling molecules. While best known for mediating TNFR1 and TNFR2 signaling, TRAF2 also modulates other receptor pathways, including MAPK, NF-κB, and Wnt/β-catenin cascades. By regulating NF-κB-inducing kinase (NIK), TRAF2 is a key activator of the alternative NF-κB pathway, linking it to inflammatory diseases, immune dysfunction, and tumorigenesis.
In the innate immune system, TRAF2 influences macrophage differentiation, activation, and survival and stimulates natural killer cell cytotoxicity. In the adaptive immune system, it represses effector B- and T-cell activity while sustaining regulatory T-cell function, thus promoting immune suppression. The lack of fine-tuning of TRAF2 activity leads to excessive NF-kB activation, driving chronic inflammation and autoimmunity.
Although TRAF2 can act as a tumor suppressor, it is predominantly described as a tumor promoter, as its expression has been correlated with increased metastatic potential and poorer prognosis in several types of cancer. Targeting TRAF2 or TRAF2-dependent signaling pathways might represent a promising anti-cancer therapeutic strategy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。